ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike

Johnson & Johnson (JNJ) reported stronger-than-expected first-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue estimates. It raised its revenue guidance for this year amid tariff chaos and boosted its quarterly dividends.Given the resilience of the drugmaker amid the potential tariff shifts under the Trump administration, investors should tap the company’s growth prospects through ETFs with the largest allocation to ...